Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis


Sanofi launches 2023 global Employee Stock Purchase Plan  


Media Update: New data from Sanofi’s diverse, differentiated oncology pipeline and portfolio to be presented at ASCO 2023


FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants


Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients